Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$5.05 USD
-0.80 (-13.60%)
Updated Jul 12, 2024 03:57 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHIO 5.05 -0.80(-13.60%)
Will PHIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHIO
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
Other News for PHIO
Phio Pharmaceuticals Shareholders Approve Key Proposals
Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying
Phio Pharmaceuticals files for $100M mixed shelf
Phio Pharmaceuticals files $100M mixed securities shelf